Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Xarelto
Synonyms :
rivaroxaban
Class :
Cardiovascular; Anticoagulants, Hematologic; Factor Xa Inhibitors
Brand Name :
Xarelto
Synonyms :
rivaroxaban
Class :
Cardiovascular; Anticoagulants, Hematologic; Factor Xa Inhibitors
Dosage forms & Strengths:Â
Adult:Â
TabletÂ
2.5 mgÂ
10 mgÂ
15 mgÂ
20 mgÂ
2.5
mg
Tablet
Orally 
twice a day
Include 75-100 mg of aspirin in this dosage regimen once daily.
The therapy is started after the successful revascularization of the lower extremity. Before the therapy, maintain the hemostasis.
Indicated for Stroke Prophylaxis with Atrial Fibrillation
20 mg orally once a day with evening meal.
TabletÂ
10 mgÂ
15 mgÂ
20 mgÂ
Oral suspensionÂ
1 mg/mlÂ
For 10-11.9 kg- 3 mg orally every 8 hours (total daily dose- 9 mg)
For 12-29.9 kg- 5 mg orally every 12 hours (total daily dose- 10 mg)
For 30-49.9 kg- 15 mg orally each day
For ≥50 kg- 20 mg orally each day
may have an increasingly adverse effect when combined with rivaroxaban
may have an increasingly adverse effect when combined with rivaroxaban
may have an increasingly adverse effect when combined with rivaroxaban
may have an increasingly adverse effect when combined with rivaroxaban
may have an increasingly adverse effect when combined with rivaroxaban
may increase the toxic effect of anti-platelet agents
may enhance the effect of each other when combined
anticoagulants increase the effect of anticoagulation of rivaroxaban
anticoagulants increase the effect of anticoagulation of rivaroxaban
anticoagulants increase the effect of anticoagulation of rivaroxaban
anticoagulants increase the effect of anticoagulation of rivaroxaban
anticoagulants increase the effect of anticoagulation of rivaroxaban
CYP3A strong enhancers of the small intestine may reduce the bioavailability of rivaroxaban
may increase the anti-coagulant action of anti-coagulants
anticoagulants increase the effect of anticoagulation of rivaroxaban
it increases the effect of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased thrombogenic effect when combined with anti- coagulant inhibitor complex
CYP3A4 inhibitors increase the concentration of rivaroxaban
CYP3A4 inhibitors increase the concentration of rivaroxaban
CYP3A4 inhibitors increase the concentration of rivaroxaban
CYP3A4 inhibitors increase the concentration of rivaroxaban
CYP3A4 inhibitors increase the concentration of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
when administered with rivaroxaban, the therapeutic efficacy of andexanet alfa may be reduced
rivaroxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
rivaroxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
rivaroxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
rivaroxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
rivaroxaban: it may enhance the toxic effect of Anti-Inflammatory Agents
the effect of rivaroxaban is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may decrease triethylenetetramine elimination, raising serum levels
may increase the anti-coagulant effect of antiplatelet agents
may increase the anticoagulant effect of Anticoagulants
may enhance the anticoagulant effect
may increase the anticoagulant effect of pentosan polysulfate sodium
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
The anticoagulant effects of ancord may be enhanced when administered concomitantly with other anticoagulants
miconazole nitrate/hydrocortisoneÂ
the activity of oral anticoagulants may be increased
it may increase the anticoagulant effect
Actions and Spectrum:Â
rivaroxaban is a broad-spectrum anticoagulant. It treats a variety of conditions that involve blood clots.Â
1-10%:Â
Back pain (2.9%)Â
Abdominal pain (2.7%)Â
Wound secretion (2.8%)Â
Dizziness (2.2%)Â
Pain in extremities (1.7%)Â
Pruritus (2.1-2.2%)Â
Insomnia (1.6%)Â
Muscle spasm (1.3%)Â
Fatigue (1.4%)Â
Blister (1.4%)Â
Syncope (1.2%)Â
Depression (1.2%)Â
Hematoma (<3%)Â
Black Box Warning:Â
It is essential to follow the dosage and administration instructions for the medication carefully. Â
Contraindication/Caution:Â
rivaroxaban should not be used in people hypersensitive to the drug itself.Â
Pregnancy consideration:Â Â
Limited data is available regarding drug-associated risks in pregnant women.Â
Breastfeeding warnings:Â Â
Insufficient data is available regarding the secretion of the drug in breast milk. Consider benefits and adverse effects in lactating women.Â
Pregnancy category:Â
PharmacologyÂ
rivaroxaban is an oral anticoagulant (DOAC) medication that acts as a Factor Xa inhibitor. Factor Xa is a protein in the blood that helps form blood clots. By inhibiting Factor Xa’s activity, rivaroxaban helps reduce the risk of clot formation. It may lead to deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. Â
Pharmacodynamics:Â Â
rivaroxaban directly blocks the activity of Factor Xa, a protein in the blood that forms blood clots. By inhibiting Factor Xa, rivaroxaban helps to reduce the risk of thrombotic (clot-forming) events such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. Â
Pharmacokinetics:Â Â
Pharmacokinetics studies how a drug is absorbed, distributed, metabolized, and eliminated by the body. The following parameters can describe the pharmacokinetics of rivaroxaban.Â
AbsorptionÂ
Peak plasma concentration is achieved in 2-4 hours. Â
The bioavailability of rivaroxaban is 80-100%.Â
The AUC decreases by 29-56% when released in the small intestine compared to gastric absorption.Â
DistributionÂ
The volume of distribution is 50LÂ
Bound protein is 92-95%Â
MetabolismÂ
rivaroxaban is metabolized primarily by the liver through the CYP3A4 and CYP2J2 enzyme pathways. Â
Elimination and excretionÂ
The drug is excreted in urine and feces. Its half-life is about 5-9 hours. The rate of total clearance is 10L/hr.Â
Administration:Â
Take the tablet orally with or without food.Â
If unable to swallow the tablet, crush it and mix it with applesauce. Â
For suspension, shake it before administration. Â
May add 150 ml of purified water to reconstitute. Â
Discard the suspension 60 days after the reconstitution.Â
Store the medication at room temperature.Â
Patient information leafletÂ
Generic Name: rivaroxabanÂ
Pronounced: Ri-varox-a-banÂ
Why do we use rivaroxaban?Â
rivaroxaban is used with aspirin to treat coronary heart disease and deep vein thrombosis. It is also a prophylaxis treatment for stroke with atrial fibrillation or significant cardiovascular events. These major events include myocardial infarction, cardiovascular death, and stroke.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
